Alliluev A P, Kotel'nikova O V, Chernyshova T F, Skirda T A, Kuvakina V I
Zh Mikrobiol Epidemiol Immunobiol. 1984 Mar(3):106-12.
The immunological effectiveness of dried group A meningococcal polysaccharide vaccine, developed at the Gabrichevsky Research Institute of Epidemiology and Microbiology, Moscow, for children aged 5-14 years was studied. The intensiveness of the immune response of children to 0.5 ml of the vaccine introduced in a single injection was evaluated by a rise in the level of agglutinating antibodies to group A meningococcal polysaccharide in the sera of the vaccinees 3-4 weeks after immunization with the following optimum doses: 25 micrograms for children aged 5-8 years, 50 micrograms for children aged 9-13 years and 75 micrograms for children aged 14 years and over. The vaccine was shown to be highly immunogenic. Antibodies to group A meningococcal polysaccharide were identified as IgM. These antibodies in a titer of 1:40 and higher could be detected in 90% of the vaccinated children in the younger age group, 7 months after immunization.
对莫斯科加布里切夫斯基流行病学与微生物学研究所研制的冻干A群脑膜炎球菌多糖疫苗针对5-14岁儿童的免疫效果进行了研究。通过在接种疫苗者的血清中，在以以下最佳剂量进行免疫接种3-4周后，A群脑膜炎球菌多糖抗体水平的升高，来评估儿童对单次注射0.5毫升疫苗的免疫反应强度：5-8岁儿童为25微克，9-13岁儿童为50微克，14岁及以上儿童为75微克。结果表明该疫苗具有高度免疫原性。A群脑膜炎球菌多糖抗体被鉴定为IgM。免疫接种7个月后，在较年幼年龄组90%的接种儿童中可检测到效价为1:40及以上的这些抗体。
